In 2009 we signed a global agreement with Hansa Medical, of Lund, Sweden, for exclusive rights to a diagnostic assay for Heparin Binding Protein (HBP) as a promising marker for severe sepsis and related conditions. Under the terms of the agreement, Axis-Shield will develop tests for HBP and seek commercial partners to incorporate the assay onto the menus of high-throughput laboratory systems.
Sepsis is an acute systemic response to infection, often with fever, tachycardia, hypotension, increased respiratory rate and abnormal white cell counts.
The mortality rate of severe sepsis is estimated at 28-50%, six times higher than from acute myocardial infarction, with annual costs in Europe alone of €7.6 billion.
Our new HBP assay was launched in 2012 and data to date suggest the test has better performance than existing markers for identification of those patients at risk of developing severe sepsis.
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.